Related Experiment Video
Updated: Mar 24, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
Interactive dose shaping part 2: proof of concept study for six prostate patients
Cornelis Ph Kamerling1, Peter Ziegenhein, Florian Sterzing
1Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, SM2 5NG, UK.
Physics in Medicine and Biology
|March 8, 2016
Summary
Interactive Dose Shaping (IDS) is a novel IMRT strategy for prostate cancer. This feasibility study shows IDS can create effective treatment plans quickly, though integral dose requires further optimization.
Area of Science:
- Radiation Oncology
- Medical Physics
- Image-Guided Therapy
Background:
- Intensity-Modulated Radiation Therapy (IMRT) planning requires balancing target coverage and organ-at-risk (OAR) sparing.
- Real-time, local dose adjustments during IMRT planning are challenging.
- A hierarchical, sequential approach to dose modification and recovery is proposed.
Purpose of the Study:
- To assess the feasibility of Interactive Dose Shaping (IDS) as a new IMRT planning strategy.
- To evaluate IDS for prostate cancer treatment planning using a small cohort.
- To determine if IDS can achieve comparable or superior plan quality to conventional methods in real-time.
Main Methods:
- Developed and utilized IDS tools within the Dynaplan treatment planning software.
- Created IMRT plans for six prostate cancer patients using the IDS strategy.
- Compared IDS plans against conventionally optimized, clinically approved plans (9 beams, co-planar).
- Physician-guided selection of IDS plans based on target coverage and OAR sparing trade-offs.
Main Results:
- IDS plans achieved comparable target coverage and OAR sparing to conventional plans.
- Mean dose differences were 0.0 Gy (boost) and 1.2 Gy (PTV).
- D98% and D2% differences were -1.1 Gy and 1.1 Gy, respectively.
- Treatment plan generation time ranged from 15-45 minutes, with local adaptations under one second.
- Average non-tumor integral dose increased by 16.4%.
Conclusions:
- IDS is a feasible IMRT planning strategy for prostate cancer, enabling rapid, local dose adjustments.
- The approach shows promise for improving treatment planning efficiency and plan quality.
- Further development is needed to address the observed increase in integral dose.

